KDev Oncology AB

KDev Oncology is the name of Karolinska Development’s fully owned company within the oncology area. The ambition with KDev Oncology is to improve focus and efficiency in this important therapeutic area by achieving synergies between projects and by recruiting top competence as well as attracting strategic partners and co-investors. As of today, the portfolio consists of Akinion Pharmaceuticals and GliGene, with the ambition to include an additional four to five new oncology projects over the coming years.